1. Home
  2. ECF vs SCLX Comparison

ECF vs SCLX Comparison

Compare ECF & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ECF
  • SCLX
  • Stock Information
  • Founded
  • ECF 1986
  • SCLX 2011
  • Country
  • ECF United States
  • SCLX United States
  • Employees
  • ECF N/A
  • SCLX N/A
  • Industry
  • ECF Finance/Investors Services
  • SCLX Biotechnology: Pharmaceutical Preparations
  • Sector
  • ECF Finance
  • SCLX Health Care
  • Exchange
  • ECF Nasdaq
  • SCLX Nasdaq
  • Market Cap
  • ECF 124.1M
  • SCLX 133.9M
  • IPO Year
  • ECF N/A
  • SCLX N/A
  • Fundamental
  • Price
  • ECF $9.19
  • SCLX $0.96
  • Analyst Decision
  • ECF
  • SCLX Strong Buy
  • Analyst Count
  • ECF 0
  • SCLX 3
  • Target Price
  • ECF N/A
  • SCLX $11.33
  • AVG Volume (30 Days)
  • ECF 57.7K
  • SCLX 184.3K
  • Earning Date
  • ECF 01-01-0001
  • SCLX 11-12-2024
  • Dividend Yield
  • ECF 6.42%
  • SCLX N/A
  • EPS Growth
  • ECF N/A
  • SCLX N/A
  • EPS
  • ECF 0.46
  • SCLX N/A
  • Revenue
  • ECF N/A
  • SCLX $50,833,000.00
  • Revenue This Year
  • ECF N/A
  • SCLX $34.42
  • Revenue Next Year
  • ECF N/A
  • SCLX $12.77
  • P/E Ratio
  • ECF $17.61
  • SCLX N/A
  • Revenue Growth
  • ECF N/A
  • SCLX 9.41
  • 52 Week Low
  • ECF $7.02
  • SCLX $0.73
  • 52 Week High
  • ECF $8.91
  • SCLX $2.63
  • Technical
  • Relative Strength Index (RSI)
  • ECF 53.97
  • SCLX 52.06
  • Support Level
  • ECF $9.18
  • SCLX $0.85
  • Resistance Level
  • ECF $9.29
  • SCLX $1.06
  • Average True Range (ATR)
  • ECF 0.11
  • SCLX 0.11
  • MACD
  • ECF -0.02
  • SCLX 0.02
  • Stochastic Oscillator
  • ECF 10.45
  • SCLX 52.73

About ECF Ellsworth Growth and Income Fund Ltd.

Ellsworth Growth and Income Fund Ltd operate as a closed-end, diversified management investment company. Its investment objective is to provide income and the potential for capital appreciation, which objectives the Fund considers to be relatively equal over the long term due to the nature of the securities in which it invests. The company invests in convertible and equity securities. It invests in various sectors, such as healthcare, financial services, computer software and services, energy and utilities, real estate investment trusts, semiconductors, telecommunications, business services, food and beverage, consumer products, transportation, consumer services among others.

About SCLX Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

Share on Social Networks: